ValuEngine Lowers Integra Lifesciences (NASDAQ:IART) to Strong Sell

ValuEngine cut shares of Integra Lifesciences (NASDAQ:IART) from a sell rating to a strong sell rating in a research report released on Thursday morning, ValuEngine reports.

A number of other equities analysts have also recently issued reports on IART. BTIG Research set a $70.00 target price on Integra Lifesciences and gave the stock a buy rating in a report on Wednesday, July 24th. JMP Securities increased their target price on Integra Lifesciences to $75.00 in a report on Thursday, July 25th. Oppenheimer set a $68.00 target price on Integra Lifesciences and gave the stock a buy rating in a report on Friday, October 25th. Wells Fargo & Co set a $62.00 target price on Integra Lifesciences and gave the stock a hold rating in a report on Friday, October 25th. Finally, BidaskClub cut Integra Lifesciences from a hold rating to a sell rating in a report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $61.82.

Shares of IART stock traded down $0.41 during mid-day trading on Thursday, reaching $58.02. The stock had a trading volume of 460,100 shares, compared to its average volume of 443,142. The firm’s 50 day simple moving average is $59.21 and its 200 day simple moving average is $56.78. The company has a quick ratio of 1.92, a current ratio of 2.92 and a debt-to-equity ratio of 1.07. Integra Lifesciences has a one year low of $42.14 and a one year high of $65.09. The firm has a market cap of $4.96 billion, a PE ratio of 23.98, a P/E/G ratio of 1.70 and a beta of 1.09.

Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings data on Thursday, October 24th. The life sciences company reported $0.68 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.03. Integra Lifesciences had a return on equity of 16.83% and a net margin of 3.99%. The company had revenue of $379.10 million during the quarter, compared to the consensus estimate of $376.85 million. During the same quarter last year, the company earned $0.59 EPS. The company’s quarterly revenue was up 3.6% on a year-over-year basis. Sell-side analysts forecast that Integra Lifesciences will post 2.74 earnings per share for the current fiscal year.

In related news, major shareholder Richard E. Caruso sold 80,000 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $61.77, for a total transaction of $4,941,600.00. Following the completion of the sale, the insider now directly owns 134,134 shares of the company’s stock, valued at approximately $8,285,457.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Peter J. Arduini sold 250,000 shares of the firm’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $60.55, for a total value of $15,137,500.00. Following the sale, the chief executive officer now directly owns 433,017 shares of the company’s stock, valued at $26,219,179.35. The disclosure for this sale can be found here. Over the last three months, insiders sold 866,249 shares of company stock valued at $52,791,780. 4.50% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Vaughan Nelson Investment Management L.P. increased its holdings in Integra Lifesciences by 1.5% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 862,680 shares of the life sciences company’s stock valued at $51,822,000 after purchasing an additional 12,728 shares in the last quarter. Eqis Capital Management Inc. acquired a new stake in Integra Lifesciences during the 3rd quarter valued at $276,000. AMG National Trust Bank increased its holdings in Integra Lifesciences by 4.7% during the 3rd quarter. AMG National Trust Bank now owns 14,652 shares of the life sciences company’s stock valued at $880,000 after purchasing an additional 659 shares in the last quarter. First National Bank of Omaha increased its holdings in Integra Lifesciences by 1.7% during the 3rd quarter. First National Bank of Omaha now owns 41,755 shares of the life sciences company’s stock valued at $2,508,000 after purchasing an additional 711 shares in the last quarter. Finally, Mackay Shields LLC acquired a new stake in Integra Lifesciences during the 3rd quarter valued at $1,739,000. 80.61% of the stock is owned by hedge funds and other institutional investors.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Recommended Story: How to find the components of the quick ratio

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.